“Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland”, Swiss Med Wkly, vol. 153, no. 1, p. 40039, Jan. 2023, doi: 10.57187/smw.2023.40039.